B
Beatrice De Vos
Researcher at GlaxoSmithKline
Publications - 16
Citations - 3228
Beatrice De Vos is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Rotavirus & Rotavirus vaccine. The author has an hindex of 11, co-authored 14 publications receiving 3130 citations.
Papers
More filters
Journal ArticleDOI
Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis
Guillermo M. Ruiz-Palacios,Irene Pérez-Schael,F. Raúl Velázquez,Hector Abate,Thomas Breuer,Sue Ann Costa Clemens,Brigitte Cheuvart,Felix Espinoza,Paul Gillard,Bruce L. Innis,Yolanda Cervantes,Alexandre da Costa Linhares,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Vesta Richardson,Doris Maribel Rivera-Medina,Luis Rivera,Belén Salinas,Noris Pavía-Ruz,Jorge Salmerón,Ricardo Rüttimann,Juan Carlos Tinoco,Pilar Rubio,Ernesto Nuñez,M. Lourdes Guerrero,Juan Pablo Yarzabal,Silvia Damaso,Nadia Tornieporth,Xavier Sáez-Llorens,Rodrigo Vergara,Timo Vesikari,Alain Bouckenooghe,Ralf Clemens,Beatrice De Vos,Miguel O'Ryan +35 more
TL;DR: Two oral doses of the live attenuated G1P[8] HRV vaccine were highly efficacious in protecting infants against severe rotavirus gastroenteritis, significantly reduced the rate of severe gastroenteropathy from any cause, and were not associated with an increased risk of intussusception.
Journal ArticleDOI
Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study.
Alexandre da Costa Linhares,F. Raúl Velázquez,Irene Pérez-Schael,Xavier Sáez-Llorens,Hector Abate,Felix Espinoza,Pio Lopez,Mercedes Macias-Parra,Eduardo Ortega-Barria,Doris Maribel Rivera-Medina,Luis Rivera,Noris Pavía-Ruz,Ernesto Nuñez,Silvia Damaso,Guillermo M. Ruiz-Palacios,Beatrice De Vos,Miguel O'Ryan,Paul Gillard,Alain Bouckenooghe +18 more
TL;DR: Two doses of RIX4414 were effective against severe rotavirus gastroenteritis during the first 2 years of life in a Latin American setting and inclusion of Rix4414 in routine paediatric immunisations should reduce the burden of rotav virus gastroEnteritis worldwide.
Journal ArticleDOI
Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.
Belén Salinas,Irene Pérez Schael,Alexandre da Costa Linhares,Guillermo M Ruiz Palacios,M. Lourdes Guerrero,Juan Pablo Yarzabal,Yolanda Cervantes,SueAnn Costa Clemens,Silvia Damaso,Karin Hardt,Beatrice De Vos +10 more
TL;DR: Two doses of RIX4414 are highly efficacious, providing cross-protection against any and severe rotavirus gastroenteritis and hospitalization to infants in Latin America and proof of concept that the monovalent G1P1A P[8] human rotav virus vaccine elicits cross- protection against the G9 strain.
Journal ArticleDOI
Efficacy of RIX4414 Live Attenuated Human Rotavirus Vaccine in Finnish Infants
Timo Vesikari,Aino Karvonen,Leena Puustinen,Shang-Qin Zeng,Evelyn Dora Szakal,Andrée Delem,Beatrice De Vos +6 more
TL;DR: RIX4414 strain of G1 human rotavirus vaccine was well-tolerated, immunogenic and efficacious in infants againstRotavirus gastroenteritis during a 2-year period, and a higher dose of this vaccine may be considered for future efficacy trials.
Journal ArticleDOI
A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis.
Beatrice De Vos,Timo Vesikari,Alexandre da Costa Linhares,Belén Salinas,Irene Pérez-Schael,Guillermo M. Ruiz-Palacios,Maria de Lourdes Guerrero,Kong Boo Phua,Andrée Delem,Karin Hardt +9 more
TL;DR: Results show prospects for widespread use of Rotarix to reduce rotavirus disease burden and warrant continued worldwide evaluation.